Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE

Key Points

• Pictet Asset Management boosted its WAVE stake by 5,024.6%, adding 790,175 shares to hold 805,901 shares (about 0.48% of the company) valued at roughly $13.83 million.
• Several other large funds — including Federated Hermes, Adage, Vanguard and Two Sigma — also increased positions, leaving institutional investors with approximately 89.73% of WVE stock.
• WAVE beat quarterly expectations (EPS ($0.13) vs. ($0.34) expected; revenue $38.25M vs. $8.45M expected), trades near $7.32 with a 12‑month range of $5.02–$21.73, and carries a consensus “Moderate Buy” average target of $27.88.

Pictet Asset Management Holding SA boosted its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 5,024.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 805,901 shares of the company's stock after acquiring an additional 790,175 shares during the period. Pictet Asset Management Holding SA owned about 0.48% of WAVE Life Sciences worth $13,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WVE. Federated Hermes Inc. lifted its position in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company's stock valued at $27,455,000 after buying an additional 3,750,140 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. Kennedy Capital Management LLC lifted its position in shares of WAVE Life Sciences by 1,489.5% during the third quarter. Kennedy Capital Management LLC now owns 540,437 shares of the company's stock valued at $3,956,000 after buying an additional 506,437 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of WAVE Life Sciences by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 3,573,746 shares of the company's stock valued at $60,754,000 after buying an additional 433,910 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of WAVE Life Sciences by 131.5% during the third quarter. Two Sigma Investments LP now owns 563,004 shares of the company's stock valued at $4,121,000 after buying an additional 319,837 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors.

WAVE Life Sciences Trading Up 3.7%

Shares of NASDAQ:WVE opened at $7.32 on Friday. WAVE Life Sciences Ltd. has a twelve month low of $5.02 and a twelve month high of $21.73. The company has a market cap of $1.38 billion, a PE ratio of -6.91 and a beta of -1.32. The company's 50 day moving average is $10.03 and its 200 day moving average is $11.21.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.21. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. The business had revenue of $38.25 million during the quarter, compared to analysts' expectations of $8.45 million. Equities research analysts predict that WAVE Life Sciences Ltd. will post -1.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other WAVE Life Sciences news, insider Chris Francis sold 33,194 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the sale, the insider owned 61,867 shares in the company, valued at approximately $931,098.35. This represents a 34.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Chandra Vargeese sold 3,228 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the completion of the sale, the insider owned 408,246 shares in the company, valued at approximately $5,490,908.70. This represents a 0.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 52,373 shares of company stock worth $757,527. 23.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have commented on WVE. Wells Fargo & Company decreased their price target on shares of WAVE Life Sciences from $27.00 to $13.00 and set an "overweight" rating for the company in a research report on Friday, March 27th. HC Wainwright cut their price objective on shares of WAVE Life Sciences from $30.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, April 14th. Weiss Ratings restated a "sell (d-)" rating on shares of WAVE Life Sciences in a report on Monday, April 20th. Canaccord Genuity Group cut their price objective on shares of WAVE Life Sciences from $52.00 to $43.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Mizuho upped their price objective on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, March 25th. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $27.88.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.